The Coldrif Cough Syrup ban in Uttar Pradesh followed the tragic death of 14 children in Madhya Pradesh. Authorities linked the syrup, produced by Shreesan Pharmaceutical, to kidney failure and other severe reactions among children in Chhindwara.
The state government moved quickly to protect public health. Drug inspectors will collect syrup samples from both government and private hospitals. These samples will be tested in a Lucknow laboratory to confirm their safety. Meanwhile, the government has stopped the sale, import, and export of the syrup until further notice.
Officials said the Coldrif Cough Syrup ban is a preventive step to avoid further harm. They added that the move will also help strengthen public trust in drug safety.
Soon after the incident, protests broke out in Madhya Pradesh and Rajasthan. Congress workers demonstrated in Bhopal and Jaipur, demanding the resignation of Deputy Chief Minister and Health Minister Rajendra Shukla. They blamed the government for failing to regulate harmful medicines.
In Jaipur, Aam Aadmi Party (AAP) workers staged protests outside Kaysons Pharma. Party leader Amit Dadhich urged authorities to shut the company down, citing corruption and negligence. He accused officials of allowing fake medicines to reach the market and endanger children’s lives.
Furthermore, health officials in Uttar Pradesh assured that strict drug testing and company monitoring would continue. The Coldrif Cough Syrup ban sends a clear message about accountability and the need for higher safety standards in India’s pharmaceutical industry.
